Tune Therapeutics, a Durham biotechnology startup co-founded by a Duke professor, announced the completion of its Series B fundraising round on Jan. 12, in which it raised $175 million to support ...

Tune Therapeutics, which has dual headquarters in Seattle and Durham, North Carolina, raised over $175 million in January. Seattle-based Umoja Biopharma raised $100 million the same week Tune and ...

The company's second-largest shareholder, Plantro, has submitted a bid to take it private, Bloomberg News reported on Monday.

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

ISELIN, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

Viking Therapeutics showcased significant clinical progress across its pipeline in 2024, with VK2735 emerging as a key driver for future growth. The company is well-positioned for Phase 3 trials ...

The LIGHTHOUSE study is a Phase I/II, open-label, dose-escalation and dose-expansion clinical trial evaluating the safety and tolerability of ATSN-201 in male patients ages six and older with a ...

A Durham Public Schools student stood before the school board this week to share some of their worst nightmares. “Imagine being a student, just like me, trying to focus on a math problem or ...

Gift 5 articles to anyone you choose each month when you subscribe. Biotech company Alterity Therapeutics is seeking to raise about $40 million following stellar results from a Phase 2 results ...

United Therapeutics said Monday that the Food and Drug Administration has cleared it to begin the first clinical trial testing whether organs from gene-edited pigs could provide a viable option ...

On Wednesday, oncology research firm Cargo Therapeutics said in a news release that it was halting a clinical trial because of poor results. The company’s 51 lymphoma patients gave some ...